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  ABSTRACT 
 
PAX8 is a transcription factor involved in the tissue-specific expression 
of several genes during development, tissue homeostasis and cancer. 
Recently, PAX8 has been reported to be an important marker for the 
diagnosis of ovarian carcinoma with a pivotal function in the tumorigenic 
phenotype of ovarian cancer cells. PAX8 is normally expressed in 
Fallopian tube secretory cells but not in ovarian surface epithelial cells; 
however, its expression is detected in the majority of high-grade serous 
ovarian carcinoma (HGSC) supporting the tubal origin of this cancer. To 
determine whether PAX8 contributes to ovarian cancer development, we 
initially conducted a transcriptome analyses to determine the distinctive 
molecular profiles of the Fallopian tube epithelial secretory cell line 
(FT194) and the ovarian cancer cell line (SKOV3), before and after PAX8 
silencing. The bioinformatics analysis revealed several GO categories 
enriched in both PAX8-silenced FT-194 and SKOV3 cells. Among those 
categories, the results showed that both “cell migration” and the “positive 
regulation of cell migration” bioprocess displayed transcriptional change 
of 5% in SKOV3 cells and the adhesion category shows change of about 
16% in SKOV3 and 14% in FT-194 cells. With respect to specific 
pathways, the highest differential changes upon PAX8 silencing were 
found in angiogenesis, Wnt, cadherin and integrin signalling pathways, in 
both cell types. 
Since migration and adhesion are important biological processes in both 
physiological and pathological conditions, migration and adhesion assays 
were performed using a primary human fallopian tube secretory cells 
(Primary hFTSECs) and a panel of ovarian cancer cell lines (SKOV3, 
KURAMOCHI, OVSAHO and PEA1). Interestingly, our results show 
that inhibition of PAX8 expression in Primary hFTSEC and in epithelial 
ovarian cancer cell lines significantly reduces the ability of the cells to 
migrate and adhere on Fibronectin and/or Collagen I substrates. 
Integrins are reported to be the major regulators of cellular attachment 
with the extracellular matrix and are required for cellular migration. In 
our transcriptome analysis, Integrin β3 was significantly downregulated 
after PAX8 silencing in SKOV3 cells. Therefore, we performed qRT-PCR 
	  on Primary hFTSEC and our panel of ovarian cancer cell lines and the 
results show a strong reduction of Integrin β3 expression in all ovarian 
cancer cell lines after PAX8 silencing, respect to the control cells. In 
parallel, we also show that loss of PAX8 does not affect the expression of 
Integrin αv, the ligand of Integrin β3 involved in ovarian cancer 
tumorigenesis. The Immunofluorescences assays of the functional 
heterodimer αvβ3 was tested in Primary hFTSEC and KURAMOCHI cell 
lines and in PAX8 silenced cells the signal was decreased. In conclusion, 
we believe that it is of great relevance to further study and decipher the 
link between PAX8 and Integrin β3 because it could help uncover the role 
of PAX8 in HGSC development. 
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1. INTRODUCTION 
 
 
1.1 Ovarian cancer 
 
Ovarian cancer (OC) is a generic term for a constellation of 
heterogeneous groups of cancer that involve the ovary. Around 240,000 
new cases of OC are diagnosed each year making it the seventh most 
common cancer and the leading cause for all gynecological cancer deaths 
worldwide. It is also the fifth leading cause of death in women with 
around 152,000 cases every year (Ferlay et al. 2015). Moreover, 
compared to many other cancers that have witnessed a significant 
decrease in mortality, the death rate of ovarian cancer has remained 
constant over the past 40 years with a 5-year survival rate of less than 
30% (Siegel et al. 2015).  
Based on the cell-of-origin, OC is divided into different types of tumors: 
epithelial (95%), germ line (3%), and sex-cord stroma (2%). Amongst 
these, the most common and lethal is the Epithelial Ovarian Cancer 
(EOC) type that is further divided into five histological subtypes: high-
grade serous carcinoma (HGSC, 68%), endometroid carcinoma (EMC, 
20%) clear-cell carcinoma (CCC, 4%), mucinous carcinoma (MC, 3%) 
and low-grade serous carcinoma (LGSC less than 5%). This classification 
is based on the pattern of differentiation and tumor cells morphology 
(Elisabetta Kuhn et al. 2011). 
After extensive histopathological and molecular study of various types of 
ovarian cancer, Kurman et al in 2016 proposed a new dualistic model of 
epithelial ovarian carcinogenesis. According to this new model the EOC 
is divided into two main groups: type I and type II tumors. Type I tumors 
include endometriosis-related tumors such as endometrioid, clear cell and 
seromucinous carcinomas; the low-grade serous carcinomas; mucinous 
carcinomas and malignant Brenner tumors. These types of tumor develop 
from benign extraovarian lesions that, after implanting on the ovarian 
surface, undergo a malignant transformation. They usually grow slowly 
and are genetically stable with characteristic gene signatures such as 
mutations in KRAS, BRAF, PTEN and CTNNB1. They are often 
diagnosed at an early stage when they confine to the ovaries and usually 
have a good prognosis, representing only 10% of the deaths from ovarian 
cancers (Kurman and Shih 2016).  
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Type II tumors are composed for the most part, of high-grade serous 
carcinomas that can be further subdivided into different subtypes. Many 
type II carcinomas develop from fallopian tube epithelial carcinomas that 
subsequently involve the ovaries and extra-ovarian sites. They are 
genetically unstable with several characteristic gene signatures such as 
TP53 mutations, BRCA1 loss and PIK3CA mutations. They are 
characterized by drastic development with high proliferative and 
metastatic features. In >75% of cases the disease is detected in advance 
stages, usually showing an intra-abdominal spread, frequently 
accompanied by ascites. Unfortunately, the Type II tumors are the most 
common, with very poor 5-year survival rate, causing 90% of all ovarian 
cancer deaths (Kurman and Shih 2016). 
 
1.1.1 Theories about the origin of HGSC 
Most cancers involving the ovaries are called “Ovarian Cancer” but many 
of them may not originate in the ovaries. The incomplete understanding 
of the origin and pathogenesis of each type of ovarian cancer may impede 
the development of prevention, early detection and treatment methods. 
The HGSC causes 80% of all malignant ovarian fatalities (Bowtell 2016). 
The low 5-year survival rate is mainly due to the loss of specific 
symptoms in the early stages of the disease and consequently the 
diagnosis is usually after the metastasis. The exact process of the 
development of HGSC is still unclear. Therefore, for a better 
comprehension of this disease it is necessary to study and understand the 
process of its origin. Although, there have been several theories proposed 
to explain the nature and the development of the HGSC. There are mainly 
two schools of thought based on the primary site of the HGSC: the 
ovarian origin and the extra ovarian origin.  
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Originally, the primary site of HGSC was attributed to the ovary and in 
particular, the ovarian surface epithelium (OSE). The "incessant 
ovulation" hypothesis is the one of the most popular theories according to 
which the ovarian surface epithelium is transformed because of repetitive 
injury to the OSE during each ovulatory cycle. This repetitive injury 
causes changes in hormone levels and an increased inflammation, leading 
to DNA damage and OSE transformation that further develops into 
HGSC. Consequently, the risk for the transformation process increases 
with higher number of ovulations and therefore, oral contraceptives that 
reduce ovulation, are associated with lesser risk of ovarian cancer 
(Fathalla 2013).  
The other theory that supports the ovarian origin of HGSC is the “OSE or 
coelomic metaplasia”. According to this theory, incessant ovulation and 
each cycle of repair drive a metaplastic change towards a more Mullerian-
type epithelium. This theory suggests that to undergo metaplasia, the cells 
retain their primitive stem-cell like pluripotent nature. The transformed 
cells exhibited the ability to acquire characteristics similar to that of 
fibroblasts and also expressed stem-cell markers like NANOG (Auersperg 
2013).  
Between 1990 and 2000, the theories that supported the ovarian origin of 
HGSC began to falter. During this period, it was observed that BRCA1 
and BRCA2 mutations were associated with increased risk for ovarian 
cancer. Therefore, women with these germ line mutation were suggested 
to undergo prophylactic tubectomy and oophorectomy (Olivier et al. 
2004; Walker et al. 2015). Surprisingly, while looking for some early 
indicators of ovarian cancer, several hidden lesions were found in the 
fallopian tubes fimbria, which were later named as serous tubal 
Incessant%ovulaCon%
OSE%or%Coelomic%metaplasia%or%Mullerian%metaplasia%
OVARIAN2ORIGIN%
HGSC%
EXTRA2OVARIAN%ORIGIN% Tubal%origin%
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intraepithelial carcinoma (STIC) (Zweemer et al. 2000; Carcangiu et al. 
2004). It is important to note that these samples did not show any ovarian 
serous carcinoma (Medeiros et al. 2006; Shaw et al. 2009). More 
importantly, while comparing the gene expression profiles of HGSC, FTE 
and OSE, HGSC and Fallopian tube secretory epithelial cells, showed 
more similarities than HGSC and OSE. In particular, they revealed that 
most of the STIC lesions harbor the same TP53 mutation as the 
concurrent HGSC, indicating their possible clonal nature (Kuhn et al. 
2012). The hypothesis that the fallopian tube is the primary site of most 
high-grade serous carcinomas start to be supported by several research 
findings. Thus, a new school of thought that supports the extraovarian 
origin of the HGSC was developed. It was proposed that for the 
transformation process of secretory epithelial cells of the Fallopian tube 
TP53 should be mutated and acquire a p53 signature (Kuhn et al. 2012). 
These cells further accumulate mutations induced by hormones that 
further promote the development of non-invasive Serous Tubal 
Intraepithelial Carcinoma (STIC) in the Fallopian tube. The proximity to 
the ovary and the paracrine factors secreted by it, possibly induces further 
neoplastic changes. These STICs, on reaching the adjoining the OSE 
surface, become fully metastatic and aggressive HGSC. The Figure 1 
shows the classical process of development from the normal Fallopian 
Tube epithelium (FTE) to the highly invasive HGSC, through 
accumulation of p53 signature and development of STIC. Designing 
mouse models for HGSC has been difficult due to the genetic complexity 
of the disease. In a recent report, Zhai et al showed a new mouse model 
for ovarian cancer that uses Ovgp1 driven Cre as a FT-specific promoter 
to inactivate Brca1, Trp53, Rb1, Nf1 and Pten. The loss of the expression 
of these specific genes in the mouse FT epithelium mimics the 
tumorigenic development of human HGSC. This evidence along with 
others, seem to suggest that the majority of the HGSC possibly originate 
as STICs in the FTE (Kim et al. 2012; Zhai et al. 2017). Recently it has 
been reported that PAX8 is expressed in the Fallopian tube secretory 
epithelial cells and its expression is retained in the HGSC cells supporting 
the tubal carcinogenesis hypothesis. 
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Fig. 1 Transformation process of secretory epithelial cells of Fallopian tube fimbria. 
Following TP53 mutations, the cells further accumulate hormone-induced mutations that 
promote the development of non-invasive STIC. The proximity to the ovary and possibly 
the paracrine factors secreted by it induces further neoplastic changes becoming fully 
metastatic and aggressive HGSC. 
 
N
or
m
al
%F
al
lo
pi
an
%T
ub
e%
ep
ith
el
iu
m
%%%
%%%
P5
3%
sig
na
tu
re
%
Se
ro
us
%T
ub
al
%
In
tr
ae
pi
th
el
ia
l%
Ca
rc
in
om
a%
(S
TI
C)
%%
In
va
si
ve
%S
er
ou
s%
Ca
rc
in
om
a%
Ho
rm
on
e%
in
du
ce
d%
m
ut
aC
on
s%%
FA
LL
O
PI
AN
"T
U
BE
"F
IM
BR
IA
"
Sp
re
ad
%to
%p
er
ito
ne
um
%o
r%o
va
ry
%
Pa
ra
cr
in
e%
fa
ct
or
s%s
ec
re
te
d%
by
%o
va
ry
%%
Introduction 
	   6	  
1.2 PAX gene family 
 
The PAired boX gene family (PAX) is a group of transcription factors 
that are well known for their role during embryogenesis. This family is 
made up of nine members (PAX1-9) and their expression is strictly 
regulated in both temporally and spatially, critical for normal embryonic 
development (Mansouri et al. 1996). PAX genes have been described for 
the first time in the Drosophila model and their expression is 
evolutionarily well conserved in many species including humans, mice, 
zebrafish, birds, frogs, flies and worms (Bopp et al. 1986; Dahl 2005). 
The PAX gene family is named after the discovery of the paired-box 
DNA binding domain that is common for all the members. On the basis of 
their structure, the PAX genes are further divided into four subgroups (I-
IV) based on the differences in two of the three regions: Paired box 
(common in all members), Octapeptide (presence or absence) and 
Homeodomain (presence, absence or truncation) (Treisman et al. 1991) 
(Fig.2). 
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Fig.2 Structural domains, expression during embryogenesis and malignancies, and 
cancer contributions of PAX family members subgroup. 
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The Paired box domain is highly sequence specific in its DNA binding 
region, it is 128 amino acid long and located at the amino-terminal end of 
the protein. The DNA–binding paired-box domain is made up of two sub-
domains named PAI and RED. The entire PAIRED domain is involved in 
its interaction with DNA and in particular, the N-terminal PAI sub-
domain interacts directly with the DNA and the C-terminal RED sub-
domain indirectly (Treisman et al. 1991). 
In addition to the Paired domain, the homeodomain can also interact with 
the DNA. This structural domain can be, in certain PAX genes, additional 
or partial. PAX3, PAX4, PAX6 and PAX7 have a three-helix 
homeodomain while PAX2, PAX5 and PAX8 have a partial one-helix 
homeodomain. Generally, homeodomains assist in sequence specific 
binding to the DNA, and, particularly, the homeodomain of the PAX 
proteins recognize the palindromic sequence TAAT(N)2–3ATTA 
(Treisman et al. 1991; Mayran et al. 2015). 
The octapeptide is an eight amino-acid domain present in all PAX 
proteins, except for PAX4 and PAX6. It is highly conserved and functions 
as a transcriptional inhibitory motif. The direct interaction of the 
octapeptide domain is functionally important for its repressive activity 
and, for example, the interaction of the octapepdtide domain of PAX 
protein is functionally important, as this repressive activity is associated 
with dysregulation of the Wnt pathway that is attributed to several cancers 
(Mayran et al. 2015). 
The PAX gene expression is critical during the embryogenic development 
and their roles are well conserved across species. Their expression is 
generally observed until the organogenesis and may persist only in a few 
specific organs in the adult. Their presence is attributed to the regulation 
of cell fate decisions and has been associated with enhanced cell-
proliferation, repression of apoptosis, inhibition of terminal differentiation 
and promotion of stem cell features (Muratovska et al. 2003). However, 
in the last decade, their aberrant expression is increasingly associated with 
several malignancies and other pathologies. Despite this association, their 
precise role in tumor progression is still obscure and it has been reported 
that their overexpression or aberrant expression does not seem to be 
sufficient to cause malignancy (Muratovska et al. 2003). During 
organogenesis, PAX1 and PAX9 are well-characterized for their role in 
skeleton, pharyngeal patterning, development of thymus and first 
branchial arch; PAX2, PAX3, PAX5, PAX6, PAX7 and PAX8 in central 
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nervous system; PAX2 and PAX8 in kidney; PAX5 in B-cells; PAX8 in 
thyroid and Mullerian system; PAX4 and PAX6 in pancreas; and PAX3 
and PAX7 in skeletal muscle (Lang et al. 2007; Blake and Ziman 2014). 
In malignancies and other pathogenesis, it has been reported that PAX 
genes such as PAX2, PAX3, PAX5, PAX7 and PAX8 have tumor 
promoting role with an anti-apoptotic, pro-proliferative and pro-
metastatic effect (Fig. 3); the other PAX genes such as PAX1, PAX4, 
PAX6 and PAX9 have not been reported to have tumor enhancing 
functions. Among the PAX genes with tumor promoting features, PAX3 
and PAX7 are involved in sarcomas, specifically Rhabdomyosarcoma, 
melanomas and neural crest tumors (Relaix et al. 2004) PAX5 in several 
B-cell malignancies (Busslinger 2004); PAX2 in several renal and bladder 
cancers (Muratovska et al. 2003); PAX4 and PAX6 are implicated in the 
cancers of the pancreas and gastrointestinal tract (Wang et al. 2008); 
PAX8 is involved in thyroid cancers, ovarian cancers, renal cancers, 
gliomas (Tacha et al. 2011). Contrarily, with respect to PAX genes 
correlated with favorable prognosis, PAX1 and PAX9 are involved in 
eosophageal cancers (Gerber et al. 2002) (Fig. 2). 
The PAX genes are also involved in cancers by producing a fusion 
oncopeptide that is constitutively expressed through chromosomal 
translocations. The best examples are PAX3-FKHR, PAX7-FKHR in 
alveolar rhabdomyosarcoma (Gerber et al. 2002), PAX5 – IGH in Non-
Hodgkins Lymphoma (Souabni et al. 2007), PAX8-PPAR in Follicular 
thyroid carcinoma (Sugg et al. 1998). It is important to note that PAX8 
exhibits role in major hallmarks for metastasis such as inhibiting cell 
death, propagating self-renewal and in Epithelial Mesenchymal Transition 
(Di Palma et al. 2014). 
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Fig.3 Overview of the roles of PAX genes involved in tumor promoting processes. 
 
1.3 The transcription factor PAX8  
PAX8 is a transcription factor that was first isolated in 1990 in mice and 
then in 1992 in humans (Poleev et al. 1992). PAX8 is now well known for 
its important role in the cell fate determination and development of 
several organs like thyroid, kidney, eyes, inner ear, brain and Müllerian 
tract (Gerber et al. 2002). Like the other PAX in the subgroup II, PAX8 is 
composed of Paired domain, an octapeptide and a truncated 
homeodomain. The gene that codes for the human PAX8 protein is 
present in Chromosome 2 at position 2q12-1447 and it is composed of 12 
exons. The translation begins from exon 2 that has the start codon. The 
exons 3 and 4 encoded for the Paired-box domain that is present in the 
amino terminal region of the protein. Exon 5 codes for the octapeptide 
while exons 7 form the truncated transactivating homeodomain (Yusuf et 
al. 2012).  
PAX8 has five different isoforms, namely, PAX8A, B, C, D and E, from 
different RNA transcripts produced as a result of alternative splicing of 8-
10 exons.  
PAX8A, which is composed of 450aa, is the longest and the most 
v(
v(
v(
v(
PAX2(
PAX3(
PAX8(
PAX5( PAX7(
TUMOR(PROMOTING(
PRO;METASTATIC( ANTI;APOPTOTIC(
PRO;PROLIFERATIVE(
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common isoform and includes all the codons from exon 2 to 12. PAX8B 
does not have exon 9. PAX8A and PAX8B, each have exon 10-11 with 
unique serine, threonine and tyrosine rich transcriptional activation 
domain unlike other isoforms. PAX8C has a shorted exon 9 as it utilizes 
an internal exon 9 5’-splice site and due to this, it has an altered reading 
frame producing the stop codon in exon 11 thereby having a shorter 
proline-rich carboxyl-terminal. PAX8D has lacks exon 8 and 9, while 
PAX8E, has exons 8-10 deleted. Both PAX8D and PAX8E have reading 
frame identical to PAX8C and produce truncated proteins. The 
transcriptional activity is higher in PAX8A and PAX8B as compared to 
PAX8C (Kozmik et al. 1993). Very little is known about the post-
transcriptional modifications of the PAX8 protein. Since there are serine 
and threonine sites in the domain of the PAX8 protein, there could be 
phosphorylated with the possible involvement of PKA (Protein Kinase A) 
(Poleev et al. 1997). However, the exact sites for phosphorylation are yet 
to be defined.  
In thyroid, PAX8 has been known to undergo sumoylation by the 
conjugation of SUMO at lysin residue 309 thereby stabilizing the protein 
by preventing its degradation (de Cristofaro et al. 2009). 
Most of the transcriptional role of PAX8 is known in thyroid context and 
it is involved in several pathways that contribute to carcinogenesis. 
Retinoblastoma (RB), a tumor suppressor, is a known positive 
transcriptional co-activator of PAX8 and interacts with its partial 
homeodomain (Miccadei et al. 2005). PAX8 also is involved with RB in a 
reciprocal relation wherein PAX8 regulates E2F1 promotor and stabilizes 
RB helping in tumor cell growth. PAX8 is also known to promote tumor 
cell survival by suppressing the expression of another well-known tumor 
supressor, TP53 through TP53inp1 (Di Palma et al. 2013). Wilms Tumor 
1 (WT1), another tumor suppressor was reported to have transcriptionally 
activated by PAX8 (Siehl et al. 2003). PAX8 is also reported to be 
involved in the activation of Bcl2, an important anti-apoptotic protein56. 
Transforming Growth Factor–b1 (TGFB1), whose role is implicated in 
the favoring the tumor microenvironment, is also reported to control 
PAX8 transcription (Hewitt SM et al. 1997).  
In addition, PAX8 is implicated in an oncogenic rearrangement in thyroid 
carcinomas caused by a translocation between chromosomal regions 2q13 
and 3p25. This rearrangement results in a fusion transcript wherein most 
of the coding sequence of PAX8 (2q13) is fused in frame with the entire 
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coding exons of PPARγ1 (3p25). The PAX8 promoter is highly active in 
thyroid follicular cells and drives the expression of the fusion transcript, 
resulting in high level expression of the fusion transcript and protein 
PPFP (PAX8-PPARγ fusion protein). Although the specific mechanism of 
PPFP action is yet to be defined, it is known that PPFP has the DNA 
binding domains of both PAX8 and PPARγ. Therefore, a plausible 
mechanism of oncogenesis is the modulation of the downstream pathways 
of PAX8 or PPARγ (Priyadarshini and Ronald 2015). Thus, PAX8 though 
primarily known as a differentiation promoting transcription factor has 
been in different contexts reported to aid in tumor progression and 
maintenance. 
 
1.3.1 PAX8 expression in normal tissues 
PAX8 is an important transcription factor involved in the development of 
various organs such as thyroid, kidney, Müllerian tract, vertebral column, 
hindbrain, eye and inner ear (Blake and Ziman 2014). It is also necessary 
for the maintenance and has been shown to be a lineage-specific marker 
of organs like thyroid, kidney and the Müllerian tract (Tacha et al. 2011). 
Because of the high sequence homology between PAX8 and the other 
members of the subgroup II (PAX2 and PAX5), some reports of PAX8 
staining in lymph nodes, pancreas, and neuroendocrine cells of stomach 
and colon cannot be considered as a fact. This is attributed to the cross-
reactivity of PAX8 polyclonal antibody used and not because of PAX8 
expression in these tissues. To resolve this issue, a monoclonal PAX8 
antibody with high specificity was used to identify PAX8 positive tissue 
(Toriyama et al. 2014).  
Consistent with the role of PAX8 as a lineage-specific marker, it has been 
shown to be express in normal adult tissues of thyroid, kidney and the 
Müllerian tract. Its expression has been demonstrated in the developing 
thyroid gland (Damante G, Tell G 2001) and it efficiently determines the 
differentiated phenotype typically seen in the adult follicular thyroid cells 
(Pasca di Magliano et al. 2000).  
In kidney, its staining was detected in the normal tissue with focal 
segmental staining of glomerular parietal epithelial cells and diffuse 
staining of collecting duct epithelial cells (Poleev et al. 1992). In the male 
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genital tract, seminal vesicles and epididymis were diffusely positive, but 
not germ cells like, Leydig cells or Sertoli cells (Ozcan et al. 2011).  
With respect to the Müllerian duct, PAX8 is detected in the embryo 
during the organogenesis and development of the Müllerian duct. 
Moreover, PAX8 is said to be involved in the formation of the epithelial 
layer (Kobayashi 2004). It is retained throughout the formation of the 
fallopian tube and uterine epithelium. In the female genital tract, strong 
and diffuse PAX8 staining was observed in the epithelial cells of the 
endocervix and the endometrium. When the epithelial layer of the 
fallopian tube differentiates into ciliated and secretory cells, PAX8 
stained only basal and secretory cells where its expression is retained and 
absent in ciliated cells (Bowen et al. 2007). 
 
1.3.2 PAX8 in cancer tissues 
The expression of PAX8 in neoplastic tissues is well studied in several 
cancers by analysing the tissue expression profiles of cancer patients. 
PAX8 is observed in carcinomas of ovary, uterus, kidney, prostrate, 
gliomas, Wilms’ tumor and Kaposi sarcoma. The first report of PAX8 in 
malignancy was in Wilms’ tumor in 1992 (Poleev et al. 1992). The 
expression of PAX8 was then reported in several human thyroid 
neoplasms (Belfiore et al. 1994). Several reports of PAX8 expression in 
cancers such as renal neoplasm, ovarian carcinomas, gliomas were 
described establishing a definite correlation between PAX8 and several 
epithelial malignancies (Hunter et al. 2015). Further, PAX8 is now known 
to be a useful immunohistological marker that helps differentiate 
Mullerian from non-Mullerian tumors (Tavanafar and Heidarpour 2014).  
Tacha et al. examined the immuno-histochemical expression of PAX8 in 
multiple normal and neoplastic tissues. Renal cell carcinomas tested 
positive for PAX8 in 90% of the cases, ovarian cancers for 79% of the 
cases and thyroid cancer for 90% of all cases (Tacha et al. 
2011). The PAX8/PPARG gene fusion, that was previously mentioned, 
was found in 30–35% of follicular thyroid carcinomas and in a 
substantially smaller fraction of follicular variant papillary thyroid 
carcinomas. This rearrangement is very occasionally found in follicular 
adenomas (Priyadarshini and Ronald 2015). 
Introduction 
	   14	  
In endometrial cancers, 84% of the cases were positive for PAX8 
expression and in cervical cancers, PAX8 was observed in 83% cervical 
adenocarcinomas whereas 98% squamous cell carcinomas cases were 
negative for the protein expression. In bladder cancers, PAX8 was 
negative in 93% of all the cases including all bladder 
adenocarcinomas. PAX8 expression was observed in only one case of 
lung cancer (99% negative) and was 100% negative in cancers of the 
colon, breast, prostate, liver, testicular, stomach, esophagus, melanoma, 
gastrointestinal stromal tumors, leiomyosarcoma, and pheochromocytoma 
(Tacha et al. 2011).  
Laury et al. conducted a study in which PAX8 immunohistochemistry 
was performed on 1357 tumors (486 tumors in whole-tissue sections and 
871 tumors in tissue microarrays, predominantly epithelial) from multiple 
organs. Nuclear PAX8 staining was present in 91% of thyroid tumors, 
90% of renal cell carcinomas (RCCs), 81% of renal oncocytomas, 91% of 
cervical epithelial lesions, and 98% of endometrial adenocarcinomas. The 
remaining tumors, such as those from the prostate, colon, stomach, liver, 
adrenal gland, head and neck, small cell carcinomas from the lung were 
PAX8 negative (Tacha et al. 2011).  
PAX8 expression and its association with ovarian epithelial cancers 
deserves a special focus as its presence in most of the tissues is well 
replicated and documented in several independent studies apart from the 
ones mentioned above. Laury et al. reported that PAX8 staining was 
present in 99% (164 of 165) of high-grade serous ovarian carcinomas, 
71% (32 of 49) of nonserous ovarian epithelial neoplasms, and all (100%) 
low-grade ovarian carcinomas and serous borderline tumors. It is 
important to mention that strong PAX8 staining was highly specific for 
ovarian serous tumors according to both Laury and Tacha et al. (Laury et 
al. 2011; Tacha et al. 2011) 
Recently, Hong-Juan Chai et al. demonstrated that PAX8 was highly 
expressed in primary epithelial ovarian cancer (PEOC) with an overall 
92% positivity. In addition, their study revealed that PAX8 expression 
level was associated with the degree of cancer cell differentiation, FIGO 
stage, and survival rate, indicating that PAX8 is a potential marker for the 
diagnosis of PEOC (Chai et al. 2017). This could be relevant in the 
therapeutic approach. Apart from the ones mentioned above, there are 
various recent reports that vouch for the specificity of PAX8 expression 
specifically in HGSC. Due to this PAX8 has become a reliable 
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immunohistological marker to identify and diagnose HGSC. 
Figure 4 highlights the role of PAX8 in organogenesis, expression in 
adult tissue in both normal and neoplastic conditions. If one observes 
closely, there seems to be a definite association between expression of 
PAX8 in normalcy and malignancy, as in many transcriptional factors that 
are involved in in development and cancers. 
 
 
 
Fig.4 Expression of PAX8 during the organogenesis, in adult tissue and cancers. 
 
1.3.3 Pathways regulated by PAX8 in ovarian cancer  
To have better insights regarding the possible underlying mechanisms by 
which PAX8, that has a normal expression in Fallopian tube is aberrantly 
retained in metastatic ovarian cancers like HGSC, several groups studied 
the gene expression analysis before and after PAX8 silencing in Fallopian 
tube cell-line and ovarian cancer cell line. 
In 2016, Elias et al, published their findings of how the epigenetic 
changes that govern the PAX8 binding sites are modified between 
fallopian tube and ovarian cancer (Elias et al. 2016). They studied the 
PAX8 cistrome by comparing three fallopian tube cell-lines (FT33, 
FT194 and FT246) and three high-grade serous cancer cell lines 
(KURAMOCHI, OVSAHO and JHOS4) before and after PAX8 
silencing. Cistrome is defined as the genome wide map of the binding 
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sites of a transcription factor. Their study showed that between fallopian 
tube and the ovarian cancer cell-lines, the ovarian cancer cells had 
significantly reprogrammed their PAX8 cistrome. Further on analysing by 
RNA-seq and ChIP-Seq, the genes that are differentially expressed 
between these two cell types were located and clustered around the PAX8 
binding sites. Additionally, on careful scrutiny of the PAX8 cistrome 
alterations, there seems to be an increase in the interactions between 
PAX8 and TEAD. This suggests that the Hippo-YAP signalling pathway, 
which is known for their important role in many cancers, could interact 
with PAX8 and be an important mediator to regulate transformation in 
ovarian cancer. Their group further investigated this relation and 
proposed that PAX8 functions differentially upon transformation and 
thereby promote cancer progression through Hippo-YAP pathway (Elias 
et al. 2016). 
To highlight the significance in exploring the PAX8 pathway in epithelial 
ovarian cancer, Kar et al. in 2017 showed that of loci that are susceptible 
to alterations in Serous Epithelial Ovarian Cancers (SOC), the putative 
PAX8 target genes with binding sites for PAX8 were enriched (Kar et al. 
2017). This is the first study that distinguishes binding sites for PAX8 as 
the governing change amongst SNP (Single Nucleotide Polymorphisms) 
that are enriched in epithelial ovarian cancer and increases its risk, much 
like Estrogen receptors in breast cancer or androgen receptors in prostate 
cancer. This study analysed the 615 Transcription factor (TF)- target gene 
sets from the two largest and available Serous Ovarian Cancer risk 
Genome-wide Association Studies data sets. They concluded that the 
PAX8 targets were the most altered amongst the gene sets. Their study 
indicated how the SOC risk was driven by a network of PAX8 and 15 
select genes such as BNC2 and HOXB7. These genes were further 
validated for their binding to PAX8 by ChIP-seq analysis (Kar et al. 
2017). 
Along the same line, Adler et al, also in 2017 investigated PAX8 cistrome 
in epithelial ovarian cancer (Adler et al. 2017). This report along with 
others demonstrated the decrease in anchorage dependent and 
independent growth in ovarian cancer cell lines (HeyA8 and IGROV1) 
upon PAX8 silencing. PAX8 cistrome in these cell-lines were 
characterized using ChIP-seq along with ChIP-seq for acetylated histone 
subunit 3 (H3K27ac) to analyze PAX8 binding sites in active chromatin. 
The two cell lines showed difference in the number of PAX8 binding sites 
corresponding with active chromatin, approximately 60% in IGROV1 and 
Introduction 
	   17	  
25% in HeyA8 cells. The enormous difference could be attributed to the 
difference in histotype of the cancer having isolated from different 
patients. This study also characterized the PAX8 binding motif and 
identified candidate PAX8 co-regulators and target genes. They 
concluded that PAX8 binding was enriched at superenhancers and 
controlled genes that encompass differentiation, development and 
tumorigenesis. They reported that amongst the many developmental 
pathways that were augmented in the PAX8 cistrome, tissue 
morphogenesis, apoptosis, EMT, Notch signalling were notable. This 
study indicates the direct and indirect regulatory gene targets of PAX8 
throughout the genome (Adler et al. 2017). 
More recently, Ghannam-Shahbari et al. in a study published in 2018 
have reported that PAX8 can directly bind to the first intron-exon 
boundary of TP53 in Fallopian tube and also to mutant TP53 in HGSC. 
The PAX8 activated mutant TP53 further causes a cytoplasmic p21 
accumulation resulting in a proliferative effect observed in HGSC 
(Ghannam-Shahbari et al. 2018). It is more than plausible that PAX8 
could have other pathways to execute its pro-oncogenic roles in HGSC. 
However, from the above studies, one can consider PAX8 as a putative 
and an important regulator of HGSC. This also indicates that inhibition of 
the PAX8 pathway or many of its downstream regulators in a 
combinatorial method could be a possible therapeutic methodology to 
contain HGSC (Ghannam-Shahbari et al. 2018).
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2. AIM OF THE THESIS 
 
In this thesis, I will discuss the role of the transcription factor PAX8 in 
ovarian carcinoma through the identification of its new putative target 
genes and downstream networks. Particularly, I will address the two 
pivotal aims of my Ph.D. project: 1) identification of PAX8 downstream 
pathways in Fallopian tube secretory cells (FT194) and epithelial ovarian 
cancer cells (SKOV3), by means of the RNA-seq strategy; 2) analysis of 
migration and adhesion properties of primary human fallopian tube 
secretory cells (Primary hFTSECs), SKOV3 and other HGSC cell lines 
following PAX8 silencing focusing on the possibility that Integrin β3 
could be involved in the modulation of these two processes.  
 
Concerning the first aim, the molecular mechanism(s) by which PAX8 
fosters High-grade serous carcinoma (HGSC) is still unclear. To 
determine how PAX8 might contribute to ovarian cancer development, 
we initially conducted a transcriptome analyses to determine the 
distinctive molecular profiles of the Fallopian tube secretory cells and 
ovarian cancer cells (FT194 and SKOV3 cell lines, respectively), before 
and after PAX8 silencing. Through a bioinformatics analysis, we 
examined several GO categories and pathways enriched in both PAX8-
silenced FT194 and SKOV3 cells. 
 
As to the second aim, based on the results obtained by RNA-seq analysis, 
we analyzed the effect of PAX8 silencing on migration and adhesion 
properties of Primary hFTSECs, SKOV3, KURAMOCHI, OVSAHO and 
PEA1 cells. The goal was to understand if these two important processes 
of cancer progression are affected by PAX8. In the last part of my study, I 
focused on Integrin β3 that is an adhesion molecule involved in both 
migration and adhesion ability of ovarian cancer cells, probably 
downstream of PAX8.
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3. MATERIALS AND METHODS 
 
3.1 Cell culture 
Immortalized Fallopian tube secretory epithelial cell line FT194 was 
provided by Dr. R. Drapkin (Boston, USA). This cell line was grown in 
DMEM-F12 medium (Euroclone) supplemented with 2% Ultroser G 
serum (PALL) and 1% penicillin/streptomycin. 
The human ovarian cancer cell line SKOV3 was provided by the 
CEINGE Cell Culture Facility (Naples, Italy). High-grade serous ovarian 
cancer cell lines KURAMOCHI and OVSAHO were obtained from the 
Japanese Collection of Research Bioresources Cell Bank (JCRB). All 
these cell lines were maintained in RPMI-1640 medium supplemented 
with 10% fetal bovine serum and 1% penicillin/streptomycin (Euroclone). 
The human ovarian cancer cell lines PEA1 and PEO14 were purchased 
from Sigma-Aldrich and were grown in RPMI-1640 medium 
supplemented with 10% fetal bovine serum, 2 mM glutamine, 2 mM 
sodium pyruvate and 1% penicillin/streptomycin (Euroclone). 
The ovarian surface epithelial cancer cell line OVCAR-3 was obtained 
from ATCC and was maintained in RPMI-1640 medium supplemented 
with 20% fetal bovine serum, 0.01mg/ml bovine insulin and 1% 
penicillin/streptomycin (Euroclone). 
3.2 Tissue samples 
Fresh FT fimbria specimens were obtained from the Department of 
Gynecology of the AOU “Federico II” Hospital of Naples, Italy, with 
approval of the institutional review board. The fimbrial tissues used in 
this study are collected from surgical procedures for benign 
gynaecological indications. Specifically, cases of inflammatory disease, 
infection, and extensive adhesions were excluded. 
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3.3 Primary human Fallopian tube secretory epithelium ex-vivo culture 
system 
The FT tissue was wash several time in 0.9 % NaCl solution and 1% 
penicillin/streptomycin until traces of blood was completely removed. To 
help the stabilization of the tissue, it was washed in CHANG MEDIUM C 
(IrvineScientific). The dissection was performed with sterilized scalpel 
and needle by cutting the tissue into very small 1mm sized pieces. The 
dissected tissue were incubated for O/N at 37°C for enzymatic digestion 
with 0.8 mg/ml of collagenase I (Sigma C9407-100MG) on 60 mm 
culture dishes supplemented with DMEM-F12 (Euroclene) with reduced 
serum 5% fetal bovine serum (Euroclone) and 1% penicillin/streptomycin 
(Euroclone). Supernatant collected After O/N digestion was centrifuges at 
1200 rpm for 5 min and the pellet composed of dissociated cells was 
plated in collagen coated 60 mm plate supplemented with DMEM-F12 
(Euroclone), 2% Ultroser G serum (PALL) and 1% 
penicillin/streptomycin (Euroclone) media. After a visual estimation of 
cells their grew in plates, epithelial-line cells that grew in clusters were 
carefully trypsinised using clonal cylinders and replated onto a fresh 60 
mm collagen coated culture plate. These cells, named Primary hFTSECs, 
were analysed for Fallopian tube secretory epithelial cell markers such as 
PAX8 and OVGP1 using Immunofluorescence. At every passage, the 
cells were verified for these markers and only them used for experiments. 
The isolation of tissues was done using the help of Dr. Antonella Izzo at 
the Prenatal Cytogenetics and Diagnostic Services at the University of 
Federico II, Naples, Italy. 
 
3.4 Cell culture transfection 
In all the experiments, PAX8 expression was transiently downregulated 
by means of RNA interference.  
For the RNA-seq experiments SKOV3 and FT194 cells were plated in 
triplicates at a concentration of 2 × 105 cells/60-mm tissue culture dish 
and were transfected after 24 hrs with 5 nM PAX8 siRNA (Ambion, Life 
Techonologies, siRNA ID s15403) or siRNA Non Targeting (Ambion, 
Life Technologies, siRNA ID 4390843) as scramble, using the 
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Lipofectamine RNAiMAX transfection reagent (Invitrogen) following the 
manufacturer’s protocol. Cells were collected 24 hrs after transfection. 
For the qRT-PCR validation experiments SKOV3 and FT194 cells were 
harvested at 24 hrs, 48 hrs and 72 hrs after transfection and PEA1, PEO14 
and OVCAR-3 after 24 hrs.  
For the migration and adhesion assays Primary hFTSEC, SKOV3, 
KURAMOCHI, OVSAHO and PEA1 cell lines were transfected with 5 
nM PAX8 siRNA (Ambion, Life Techonologies, siRNA ID s15403) or 
siRNA Non Targeting (Ambion, Life Technologies, siRNA ID 4390843) 
as scramble and harvested 48 hrs after transfection. 
 
3.5 RNA, cDNA and qRT–PCR  
Total RNA was extracted using the RNeasy Mini kit (Qiagen). Human 
Fallopian tube RNA was purchased from Origene (CR559726). The 
cDNA was synthesized using the iScript cDNA Synthesis kit (BIORAD, 
Hercules, CA). Real-time qPCR analysis was performed using the IQTM 
SYBR Green PCR Master Mix (BIORAD) in a CFX96 Real-Time PCR 
Detection System (BIORAD) for the following genes using gene-specific 
primers (Table 1).  
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Table 1. Sequences of primers used in qRT-PCR  
 
 
3.6 RNA-seq and data mining 
After 24 hrs of transfection with siCTR and siPAX8 of FT194 and 
SKOV3 cells, 2 µg of total RNA was extracted and sent to the 
Genomics4Life Company (University of Salerno, Italy). Three 
independent silencing experiments were performed for each condition 
(siPAX8 or control) and processed using RNA-seq technology. The 
extracted RNA samples were sequenced by the Illumina HiSeq 1500 
platform using a resolution at 100 base-pairs with paired-end reads. 
Analysis was performed using the RAP (RNA-Seq Analysis Pipeline) 
available on https://bioinformatics.cineca.it/ (D’Antonio et al. 2014). The 
sequences quality check, the mapping, the transcriptomes assembling, and 
the differential expression analyses were performed using the default 
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parameters on RAP. An alpha level of 0.05 was used for all the statistical 
tests. Gene expression data were submitted on Gene Expression Omnibus 
(GEO) database with accession number GSE79572. 
 
3.7 Pathway analysis  
Gene ontology (GO) and Panther pathway analysis have been performed 
using the GeneCodis tool (http:// genecodis.cnb.csic.es) previously 
described in references (Carmona-Saez et al. 2007; Tabas-Madrid et al. 
2012).  
 
3.8 Cytoscape analysis 
The Cytoscape v3.6 Core, an open source software package 
(www.cytoscape.org/) with an accessible Java application programming 
interface (API) using the Java programming language has been used for 
the network analysis of our RNA-seq data. For the analysis the following 
parameters have been applied for investigating biological-molecular 
network between PAX8 and ITGB3:  
Node: Represents single gene/protein  
Color node: Represents only gene family and their molecular-biological 
pathways 
Size node/ size label: Represents the gene expression level (up/down 
regulated) or the importance and strength of a node inside specific 
network 
Edge: Represents the biological-molecular interactions  
Color edge: Represents the importance and strength of molecular 
interactions 
Size edge/ edge betwenness: Represents the weight of interactions  
Length edge: Represents the position of node inside biological network 
Directed network: Represents the direction of PPI between source-target 
The molecular networks are realized applying several parameters to 
investigate new important biological interactions related to our 
gene/protein list used as starting point. Here, PAX8 has been used as the 
starting point to obtain the biological network. 
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3.9 Migration assay 
Migration assays were performed using Ibidi cell migration technology 
(Ibidi, Martinsried, Germany). PAX8 was silenced in Primary hFTSECs, 
SKOV3, KURAMOCHI, OVSAHO and PEA1 cell lines as described 
before. After 24 hrs, both Scramble control and PAX8 silenced cells were 
seeded in each chamber at a density of 3  ×  105 cells/reservoir in 70 µL of 
normal medium for 24 hrs. The medium was then replaced with fresh 
medium and the cells were treated with 10 ug/ml of Mitomicyn C (Sigma 
M4287-2MG) for 1 h at 37°C. After the incubation, the chambers were 
removed and cells were further incubated in normal medium. Cells were 
photographed (1:1 magnification), and the area covered by cells within a 
defined area in the gap measured using NIH ImageJ (rsb.info.nih.gov/ij) 
software. 
 
3.10 Adhesion assay 
Coverslips were coated with Fibronectin (10 µg/ml; Calbiochem, Cat N. 
341635) or Collagen I (10 ug/ml; Invitrogen, Cat N. A10483-01) in PBS 
1X for 1h at 37°C. PAX8 was silenced in Primary hFTSECs, SKOV3, 
KURAMOCHI, OVSAHO and PEA1 cell lines as described before. After 
48 hrs, 40 × 103 of both scramble controls and PAX8 silenced cells were 
plated on the top of coated coverslips in triplicates for 2 hrs at 37°C. After 
incubation, the coverslips were washed with PBS 1X, fixed in 4% 
paraformaldehyde for 10 min and stained with HOECHST. The 
experiment was repeated three times (n = 3) for each cell lines. Images 
were acquired using Confocal microscope (ZEISS LSM 700). For each 
coverslip, 10 images were acquired and analyzed using ImageJ software.  
 
3.11 Immunofluorescence and Confocal Laser Scanning Microscopy 
After 24 hrs of transfection with siCTR and siPAX8 as described before, 
50 x 103 of Primary hFTSECs cells and KURAMOCHI cells were spitted 
on glass coverslips and maintained in culture for 24 hrs at 37 °C.  
The cells were fixed in 4% paraformaldehyde in PBS 1X for 20 min at 
room temperature and incubated for 30 min in 10% FBS in PBS 1X. The 
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coverslips were subsequently incubated for 1h with mouse monoclonal 
anti-αvβ3 LM609 (Millipore Co.) and rabbit polyclonal anti-PAX8 diluted, 
respectively, 1:100 and 1:1000 in 4% FBS in PBS 1X. After PBS 
washing, the cells were incubated for 30 min with Alexa Fluor-546 goat 
anti-mouse IgG (Vinci Biochem) Alexa Fluor-488 goat anti-rabbit IgG 
(Vinci Biochem) both diluted 1:200 in 4% FBS in PBS 1X. After final 
washings with PBS 1X, the coverslips were mounted on a microscope 
slide using a 50% solution of glycerol in PBS 1X with Heoechst (1:3000).  
 
Experiments were carried out on an inverted and motorized microscope 
(Axio Observer Z.1) equipped with a 63X/1.4 Plan-Apochromat 
objective. The attached laser-scanning unit (LSM 700 4X pigtailed laser 
405-488-555-639; Zeiss, Jena, Germany) enabled confocal imaging. For 
excitation, 405, 488 and 555nm lasers were used. Fluorescence emission 
was revealed by Main Dichroic Beam Splitter and Variable Secondary 
Dichroic Beam Splitter. Double and/or triple staining fluorescence images 
were acquired separately using ZEN 2012 software in the blue, green 
and/or red channels at a resolution of 1024 x 1024 pixels, with the 
confocal pinhole set to one Airy unit and then saved in TIFF format. 
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4. RESULTS 
 
4.1 Identification of PAX8 downstream target genes in FT194 and 
SKOV3 cells by means of RNA-seq analysis 
 
Recently, it has been suggested that high-grade serous ovarian carcinoma 
(HGSC) arises from precursor lesions in the Fallopian tube fimbria. 
PAX8 is a transcription factor expressed in Fallopian tube secretory cells 
and its expression is retained in HGSC cells confirming the tubal origin 
theory. The research group of Dr. Zannini has previously demonstrated 
that PAX8 has a pivotal role in the tumorigenic phenotype of ovarian 
cancer cells. Infact, PAX8 silencing in ovarian cancer cells strongly 
suppressed anchorage-independent growth in vitro and inhibited 
tumorigenesis in vivo in a nude mouse xenograft model (Di Palma et al. 
2014). Based on these evidences, it is plausible that PAX8 is involved in 
the development and progression of ovarian cancer. However, its specific 
function in Fallopian tube secretory cells and ovarian cancer cells is still 
unknown.  
To uncover the downstream gene network governed by PAX8 in both 
Fallopian tube secretory cells and ovarian cancer cells, we analyzed the 
transcriptome of Fallopian tube secretory cells (FT194) and ovarian 
cancer cells (SKOV3) using an RNA-seq strategy. To this end, FT194 and 
SKOV3 cells were transiently transfected with PAX8 siRNA (siPAX8) or 
siRNA Non Targeting (siCTR) as scramble. Three independent silencing 
experiments were performed for each cell line. After 24 hrs, total RNAs 
were prepared and sent to the Genomix4life Company (University of 
Salerno) and submitted to the Illumina HiSeq 1500 platform for 
sequencing libraries generation. The raw data were analysed in 
collaboration with Prof. Cocozza (Department of Molecular Medicine and 
Medical Biotechnology, University of Naples Federico II, Naples, Italy) 
and processed with FDR-adjusted p-value ≤ 0.05. The results showed that 
467 genes were significantly modulated by PAX8 silencing in both cell 
lines. The decrease of PAX8 expression was analyzed for confirmation of 
the silencing and 80% of decrease in siPAX8-cells with respect to siCTR-
cells demonstrated efficient silencing.  
In FT194 cells 166 genes were affected by PAX8 silencing of which 119 
were downregulated and 47 were upregulated with respect to the 
scramble. In SKOV3 cells, 301 genes were significantly modulated after 
PAX8 silencing and among the total genes, 214 genes were 
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downregulated and 87 were upregulated with respect to the scramble (Fig. 
5). 
 
 
 
Fig. 5 Schematic representation of the genes significantly modulated after the RNA-seq 
analysis. The genes were divided in downregulated and upregulated in both siPAX8-
FT194 and siPAX8-SKOV3 cells. 
 
4.2 Identification of shared and exclusive sets of genes in FT194 and 
SKOV3 cells regulated by PAX8 
 
To understand how PAX8 is involved in both physiological and 
pathological states, Venn diagrams were constructed to highlight the 
common and distinct sets of genes affected by PAX8 silencing in FT194 
and SKOV3 cell lines (Fig. 6). Among the significantly downregulated 
genes, 167 were exclusively downregulated in siPAX8-FT194, 72 genes 
in siPAX8-SKOV3 cells and 47 were commonly downregulated in both 
(Fig 6A). With respect to the significantly upregulated genes, 15 were 
commonly upregulated in both cell lines and 72 and 32 genes were 
exclusively upregulated in siPAX8-FT194 and siPAX8-SKOV3 cells 
respectively (Fig 6B). The complete lists of shared and distinct genes 
modulated upon PAX8 silencing in both these cell lines are reported in 
Tables 2A and 2B. 
In particular, the common down- and up-regulated genes, such as PSAP, 
FGF18, CDH6, ROR1, RBPJ and DNMT3B, could be looked as 
promising putative targets of PAX8 with most of them already reported 
having roles in cell proliferation, cell survival and tumorigenic process. 
At the same time, the genes modulated upon PAX8 silencing exclusively 
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expressed in FT194 or in SKOV3 cells could reflect the continuous 
process that distinguishes itself from the precancerous to the cancerous 
condition. In addition, there is a possibility that the tumorigenic process 
might itself promote the expression of some genes making them available 
for PAX8 transcriptional regulation. 
  
 
 
 
 
 
 
Fig.6 Venn diagram of modulated genes upon PAX8 silencing in FT194 and SKOV3 
cells: 
(A) Overlap and differences of downregulated genes following PAX8 silencing between 
FT194 and SKOV3 cells 
(B) Overlap and differences of upregulated genes following PAX8 silencing between 
FT194 and SKOV3 cells.  
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Table 2A: List of shared and exclusive genes downregulated upon PAX8 silencing in 
FT194 and SKOV3 cells. 
 
 
 
Table 2B: List of shared and exclusive genes upregulated upon PAX8 silencing in 
FT194 and SKOV3 cells. 
NAME) TOTAL) UPREGULATED)GENES)
SKOV3'FT194- 15- ANKRD1- F3- G3BP2- TGFB2- MAPK1IP1L- TOMM20- MBTPS1- DNMT3B- PTPN1- MSRB3- MET- RBPJ-
TCEB3-WDR1-STX12--
-
SKOV3- 72- DIO2- ZCCHC3- NTN4- NGRN- TRAPPC2- CALU- MOK- DCBLD1- PTPMT1- FGF1- C1D- AHRR,PDCD6-
LOC100507412,RN45S- PCSK7- CPA4- CIRBP- SERPINE1- C6orf120- PODXL- CCDC80- DOCK10- PYGO2-
P4HA3-MCFD2-DSEL-MYPN-LPXN-CCND3-CHFR-MAP2K4-GRWD1-CCBE1-UBE2G1,ZZEF1-BOD1-NCF2-
ODZ2-ERRFI1-CCIN-SERPINB5-ATG12-CGB8-FLRT2-AIM1-ROS1-C7orf58-ALS2CL-FRMD6-KRT5-SSFA2-
PIP4K2A- SOCS7-NT5E- ESYT2- SMAP1-ARTN- SCRN1-DKK1- EFEMP1-RFK- SGK1-CCDC68-CRK- FOXD1-
PGM2L1-PCDH10-SEMA7A-ZFAND3-IFFO2-CCNC-RCAN1-KHNYN-POLR3F--
-
FT194- 32- CMPK2- RAD54L2- DDX58- IFIT1- SP110- PTPN13- DCN- PAPPA- RHOB- CCL20- GBP1- SERPINB2- OAS3-
PDZD2- IFIH1- NCOA7- OAS2- RSAD2- PTGS2-MX1- ZCCHC2- CYP1B1- DHX58- DDX60L- HMGA2- FARP2-
MX2-NRK-FPR1-THBD-ST6GALNAC5-THBS2--
-
Table)3B:)List)of)shared)and)exclusive)genes)upregulated)upon)PAX8)silencing)in)SKOVB3)and)FT194)cells))
-
NAME) TOTAL) DOWNREGULATED)GENES)
SKOV3'FT194- 47- NUP35-ANXA2-HDGFRP3-STX3-DUSP11-AP1G1-ENPP4-PHLDA3-PSAP-ENPP1-EPRS-RHPN2-C10orf46-
GPR63-CDK2AP1-H2AFY2-PPME1- LMLN-KITLG-CDH6a- FAM107B-C1orf186-BLCAP-TEX30- LONRF1-
DIAPH1-FGF18-TCN2-ROR1-AKR1B1-TGOLN2-KAZN-PHTF2-ARL4C-MAL-ADCY9-PPAP2B-PAX8-ARL5A-
MAL2-MRE11A-HTATSF1-GPR56-PTGIS-ANXA2P2-ABCC4-SLC35B4--
-
SKOV3- 167- ACTB- TSPAN1- RAB12- OSBPL11- L1CAM- OSBPL10- LRRC20- RRAD- ANKRD34B- RNF38- HES2- SMC5-
FAM3C-PRKAA2-KCNH3-LMAN1-ST3GAL2-AFF1-TAF4B-IFNGR1-FHDC1-CGNL1-CA13-SYPL1-MKNK2-
SLC39A10- AMMECR1- ZNF114- GAS2L3- CERK- BAG4- SASH1- C6orf228- TBC1D13- C7orf29,LRRC61-
TUBB2B-GTF2E1-ABCC3-PLCH1-CLDND1-MBP-CYB5R4-SLC39A14-AKR1B10-CELSR2-PDZK1-FOXN3-
PIK3R1-GRIN2B-CIAPIN1-CORO1C-RNFT1-UPP1-SHROOM2-FAM45A,FAM45B-ANKRD33B-ZNF702P-
ID4- PPM1B- PER1- SLC44A1- CDH16- PCDH20- ADAM10- RNF130- CBS- KIF12- KLHL15- ZNF28- ATP8B2-
EGFR-MIR4723,TMEM199-DICER1-DPP4-ITGB3-DENND1B-SGK2-BASP1P1-USP18-RAB3D-DCUN1D4-
SNTB1-PGGT1B-CNKSR3-CHST15-MCAM-TYW1-GCH1-TRIM2-C12orf23-FNDC5-IGFN1-USP2-TERF1-
SORT1-CRYAB-GMCL1-WNT7A-MXRA5-AGL-RNF144B-ASRGL1-MPHOSPH6-QPRT-AATF-LIN7C-NXT2-
C2orf72-RRM2-BCAT1-SLC7A11-ADAMTS9-TMSB4X-TPK1-KPNA6-ATP8A1-CHST2-THBS1-CYP4F11-
RNF145- ADAMTS5- FLJ26245- SYTL2- UBE2H- DCAF12L1- RAB11FIP2- ABI2- PTPRB- FIGN- PAFAH1B2-
TCF12- PMAIP1- WDR44- DCUN1D3- SLC30A6- EPHA4- NEBL- DSC2- CNOT6- ZNF611- MYO10- MAP2-
KCNS3- SLC26A2- HDHD2- SLAIN1- PLXNC1-MGST1- NUPL1- COL12A1- KCTD5- RCBTB2- CANT1-MTPN-
FN1-UBE2D1-ZCCHC24-TMTC2-TRIM24-FAM174B-C10orf26-TMCO7-GUCY1B3-ARHGEF1-ANKRD52-
RC3H2-ZNF618--
-
FT194- 72- KLHL13- ZNF185- PPARGC1A-WASF1- PLAU- KLHL14- TLL2- CHRD- CLGN-NGFR- ARHGEF37- FLG- GAS7-
TGFBR3- RGS20- ILDR2- SPON1- MMD- CD24- AP1M2- TNFSF4- THY1- ADAMTS14- ZBED2a- PLCB4-
ADAMTS1- LOC643201- NOV- MPP7- SHISA2- ST3GAL1- SOX17- GDF6- ANK3- RASGEF1B- CNTN4-
C13orf15- SULF2- ADORA1-MEGF9- KLRG2- ITGB8- DANCR,SNORA26- SLC6A6- BAALC- CTHRC1- G0S2-
TMEM117-AIF1L-GJB2-PRKAG2-FAT2-MST1-DCDC2-OXTR-SDC2-INHBB-KIAA1456-BTBD11-CA2-NID2-
SLC47A1-CDH5-PDE1A-COL13A1-IGFBP5-TMEM170B-CTGF-EPHB1-GPRC5C-DKK1-CDKN1C--
-
Table):)List)of)shared)and)exclusive)genes)downregulated)upon)PAX8)silencing)in)SKOVB3)and)FT194)cells-
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4.3 Validation of RNA-seq data by qRT-PCR 
 
To validate the data obtained by the RNA-seq analysis, we performed 
qRT-PCR for 13 representative genes, including PAX8. For all the 
selected genes, we firstly confirmed the differential expression between 
SKOV3 cells and FT194 cells. The results show that PAX8 is expressed 
at similar levels in these two cell types, supporting the hypothesis that 
PAX8 is not overexpressed in epithelial ovarian carcinoma but its 
expression is retained from the Fallopian tubes epithelial cells, the 
suggested cell of origin (Fig. 7). Firstly, according to the RNA-seq 
results, the genes analyzed by qRT-PCR follow the same trends in FT194 
and SKOV3 cells confirming their differential expression. Secondly, the 
same genes were validated in siPAX8-FT194 and siPAX8-SKOV3 cells 
with respect to the siCTR-cells 24 hrs, 48 hrs and 72 hrs after silencing 
(Fig 8A and 8B). In accordance with the RNA-seq results, we confirmed 
that genes like PAPPA, CHRD, ZBED2 and SERPINB2 were 
preferentially or exclusively expressed in FT194 cells and after PAX8 
silencing CHRD and ZBED2 were downregulated and PAPPA and 
SERPINB2 were upregulated with respect to the siCTR-FT194 cells. In 
parallel, genes like BOD1, DIO2, WNT7a and KIF12 are preferentially or 
exclusively expressed in SKOV3 cells. Upon PAX8 silencing, BOD1 and 
DIO2 were upregulated and WNT7a and KIF12 were downregulated in 
siPAX8-SKOV3 cells with respect to siCTR-SKOV3 cells. The genes 
commonly expressed in both these cell lines were ANXA2, ROR1, 
CDH6, and FGF18 and all were downregulated after the PAX8 silencing. 
To strengthen our observations, we successfully validated the differential 
expression of all the above mentioned genes in human Fallopian tube 
RNA and OVCAR-3, PEA1, PEO14 ovarian cancer cell lines (Fig. 9) and 
for PEA1 24 hrs after transient transfection with PAX8 siRNA or 
scramble siRNA (Fig. 10). 
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Fig. 7 Expression level of 13 genes measured on total RNA prepared from FT194 and 
SKOV3 cells. The values are means ±SD of three experiments in duplicate, normalized 
by the expression of IPO8 and expressed as fold change with respect to FT194 cells. 
 
  
	  
	  
	  
A 	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Fig. 8A and 8B Expression levels of some representative genes measured on total RNA 
prepared from FT194 and SKOV3 cells transiently transfected with PAX8 siRNA or 
scramble siRNA 24 hrs (white bars), 48 hrs (black bars) and 72 hrs (grey bars) after 
transfection. The values are means ± SD of three independent experiments in duplicate, 
normalized by the expression of IP08 and expressed as fold change with respect to the 
cells transfected with the scramble siRNA, whose value was set at 1.0. p-value was 
calculated by t-test 0.001 ≤ p ≤ 0.1.  
 
 
Fig. 9 Expression levels of 13 genes measured on total RNA prepared from human 
Fallopian tubes, OVCAR3, PEA1 and PE014 cells. The values are means ± SD of three 
independent experiments in duplicate, normalized by the expression of IP08 and 
expressed as fold change with respect to human Fallopian tubes, whose value was set at 
1.0. p-value was calculated by t-test 0.001 ≤ p ≤ 0.1. 
 
	  B 	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Fig. 10 Expression levels of some representative genes measured on total RNA prepared 
from PEA1 cells 24 hrs after transient transfection with PAX8 siRNA or scramble 
siRNA. The values are means ± SD of three independent experiments in duplicate, 
normalized by the expression of IP08 and expressed as fold change with respect to the 
cells transfected with the scramble siRNA, whose value was set at 1.0. p-value was 
calculated by t-test 0.001 ≤ p ≤ 0.1. 
 
4.4 Pathways and biological processes modified by PAX8  
 
The pathways regulated by PAX8 in ovarian cancer cells and Fallopian 
tube secretory cells are still unexplained. To categorize PAX8 associated 
pathways in siPAX8-FT194 and siPAX8-SKOV3 cells, Gene Ontology 
(GO) and Panther pathway analyses were performed using Gene 
annotations co-occurrence discovery web-based tool (GeneCodis; 
http://genecodis.dacya.ucm.es/). Processing all the dysregulated genes 
(301 for SKOV3 and 166 for FT194), several significant GO categories 
were enriched. In details, signal transduction, cell adhesion, blood 
coagulation, and multicellular organismal development were statistically 
enriched in both cell lines. To underline the most important biological 
pathways involved in siPAX8-FT194 and siPAX8-SKOV3 cells, 10 
statistically enriched categories with highest number of genes and lowest 
corrected p-value were chosen (p-values have been obtained through 
Hypergeometric analysis corrected by FDR method) (Fig. 11A and 12A). 
In Table 3 and 4 are reported the number of the genes, the corrected p-
values and the complete list of the genes for the 10 biological process 
enriched in FT194 and SKOV3 cells after PAX8 silencing. It is important 
to note that in the SKOV3 cancer cell line, the silencing of PAX8 affected 
the migration bioprocess. The migrating ability of cancer cells is an 
important feature in tumor progression and the consequent metastasis of 
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the disease. Particularly, the GO results showed that both “cell migration” 
and the “positive regulation of cell migration” categories displayed 5% of 
the transcriptome changes in SKOV3 cells upon PAX8 silencing. 
Interestingly, the “cell adhesion” GO category affected both siPAX8-
FT194 and siPAX8-SKOV3 cells and displayed 16% of overall 
transcriptome changes in SKOV3 cells and 14% in FT194 cells following 
PAX8 silencing. Panther pathway analysis was performed to further 
investigate the functional associations of the modulated genes following 
PAX8 knockdown. The results showed that the highest differential 
transcriptome changes in both cell lines were found in Wnt, Cadherin, 
Integrin, TGF-beta signaling pathways and angiogenesis process (Fig 11B 
and 12B). The results showed in GO and Panther analyses are consistent 
with each other, probably due to the strong downregulation of genes like 
Wnt7a, Cdh6, Cdh16, βActin and Integrin β3. The modulation of these 
processes by PAX8 could highlight a new role of this transcription factor 
in HGSC development. 
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Fig. 11 Biological processes and pathways altered in siPAX8-FT194 cells. (A) GO 
categories enriched for genes modulated upon PAX8 silencing in FT194 cells. Pie-chart 
with the 10 GO enriched categories with highest number of genes and lowest FDR 
corrected p-value (<0,05). (B) Panther pathways enriched for genes modulated upon 
PAX8 silencing in FT194 cells. 
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Fig. 12 Biological processes and pathways altered in siPAX8-SKOV3 cells. (A) GO 
categories enriched for genes modulated upon PAX8 silencing in SKOV3 cells. Pie-chart 
with the 10 GO enriched categories with highest number of genes and lowest FDR 
corrected p-value (<0,05). (B) Panther pathways enriched for genes modulated upon 
PAX8 silencing in SKOV3 cells. 
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Table 3: 10 statistically enriched GO categories with highest number of genes and 
lowest corrected p-value were chosen (p-values have been obtained through 
Hypergeometric analysis corrected by FDR method). In the list are reported the number 
of the genes, the corrected p-values and the complete list of the genes enriched in FT194 
cells after PAX8 silencing. 
 
 
 
 
 
&
Z` 
Number 
of genes 
Corrected 
p-values 
GO category List of genes 
17 0.00316167 Signal transduction CCL20, SP110, ADORA1, KITLG, DKK1, 
NGFR, EPHB1, RHPN2, IGFBP5, ADCY9, 
PDE1A, TNFSF4, FGF18, PLAU, MET, 
ANK3, MX1 
13 0.000644665 Cell adhesion KITLG, CDH6, CDH5, ITGB8, GPR56, 
CNTN4, NID2, RHOB, LMLN, PDZD2, 
THBS2, FAT2, CTGF 
12 0.0325062 Multicellular 
organismal 
development 
HMGA2, DKK1, NGFR, GAS7, TLL2, 
ITGB8, RHOB, SHISA2, PAX8, MET, 
FLG, COL13A1 
11 0.00228239 Blood coagulation SERPINB2, PSAP, PTPN1, RHOB, 
ABCC4, PDE1A, PLAU, TGFB2, WDR1, 
F3, THBD 
9 0.022979 Cell differentiation NGFR, TLL2, ILDR2, MAL, RHOB, 
PAX8, PAPPA, INHBB, COL13A1 
8 0.000775251 Angiogenesis SOX17, EPHB1, ANXA2, CYP1B1, 
THY1, FGF18, PLAU, TGFB2 
7 0.00289927 Cytokine-mediated 
signaling pathway 
MX2, OAS3, PTPN1, OAS2, IFIT1, MX1, 
GBP1 
6  0.000613639 Type I interferon-
mediated signaling 
pathway 
MX2, OAS3, PTPN1, OAS2, IFIT1, MX1 
5 0.00232654 Response to 
wounding 
NGFR, TGFB2, MET, F3, CTGF 
5 0.00277451 Kidney 
development 
SULF2, PAX8, DCN, CA2, ADAMTS1 
Results 
	   38	  
 
 
 
Table 4. 10 statistically enriched GO categories with highest number of genes and 
lowest corrected p-value were chosen (p-values have been obtained through 
Hypergeometric analysis corrected by FDR method). In the list are reported the number 
of the genes, the corrected p-values and the complete list of the genes enriched in 
SKOV3 cells after PAX8 silencing. 
 
 
 
 
 
 
Skov3&&
&&&&&Ft194&
Number 
of genes 
Corrected 
p-values 
GO category List of genes 
22 1.13382e-05 Cell adhesion L1CAM, MCAM, THBS1, DCBLD1, 
KITLG, DSC2, LPXN, CDH6, PCDH20, 
DPP4, ITGB3, FLRT2, CDH16, PLXNC1, 
GPR56, FN1, CELSR2, AATF, EPHA4, 
LMLN, PCDH10, COL12A1 
22 0.0299607 Signal 
transduction 
MAP2K4, IFNGR1, KITLG, LPXN, DKK1, 
MYO10, ARTN, RCAN1, FGF1, PRKAA2, 
PIK3R1, RHPN2, CORO1C, ODZ2, 
CCND3, PLXNC1, ADCY9, FGF18, EGFR, 
CANT1, MET, RRAD 
21 0.00852199 Multicellular 
organismal 
development 
TCF12, L1CAM, SHROOM2, SORT1, 
WNT7A, DKK1, NGRN, FGF1, GMCL1, 
CCBE1, PLXNC1, FAM3C, CELSR2, 
CHST2, EPHA4, PAX8, CCIN, EGFR, 
MET, ADAMTS9, SEMA7A 
16 0.000592788 Blood coagulation LMAN1, L1CAM, THBS1, SLC7A11, 
PIK3R1, CRK, GUCY1B3, PSAP, PTPN1, 
FN1, CALU, ABCC4, TGFB2, WDR1, F3, 
SERPINE1 
16 0.0113474 Transmembrane 
transport 
KCNS3, SLC44A1, SLC26A2, SLC7A11, 
KCNH3, ADCY9, ATP8A1, ATP8B2, 
SLC35B4, ABCC4, SLC39A14, SLC30A6, 
ABCC3, SLC39A10, NUPL1, NUP35 
11 0.0303045 Protein 
phosphorylation 
SGK1, MAP2K4, ADAM10, CDK2AP1, 
MKNK2, PRKAA2, CCND3, ROS1, EGFR, 
TGFB2, SGK2 
10 0.00612199 Platelet activation THBS1, PIK3R1, GUCY1B3, PSAP, FN1, 
CALU, ABCC4, TGFB2, WDR1, SERPINE1 
7 0.00757332 Positive regulation 
of cell migration 
ADAM10, THBS1, FGF1, PIK3R1, PODXL, 
EGFR, F3 
6 0.0220931 Cell migration SHROOM2, THBS1, PODXL, FN1, TGFB2, 
ABI2 
4 0.010583 Response to 
progesterone 
stimulus 
THBS1, NCF2, PIK3R1, TGFB2 
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4.5 Analysis of the migration ability of Fallopian tube secretory cells 
and ovarian cancer cell lines after PAX8 silencing 
 
One of the most important feature of ovarian cancer is its high rate of 
metastasis. In fact, when this disease is diagnosed, the patient already has 
ovarian mets in the peritoneum and in other organs. This happens mainly 
due to the total lack of symptoms and absence of early stage biomarkers, 
resulting in very late diagnosis.  
Therefore, cellular migration and adhesion are important characteristics in 
the HGSC progression and metastasis and it is important to consider them 
as closely related. Cell migration requires a dynamic interaction between 
the cells and the substratum on which they attach and move. Changes in 
the adhesion molecule repertoire may correspond to changes in migratory 
properties conferring a more invasive phenotype to cancer cells. For 
further experiments, primary human fallopian tube secretory cells 
(primary hFTSCs) that represent the normal physiology has been used. To 
explore the migratory ability of Fallopian tube secretory cells and 
epithelial ovarian cancer cells, before and after PAX8 silencing, migration 
assays were performed using the Ibidi cell migration technology. The 
results showed that PAX8 silencing significantly affects the migratory 
properties showing a reduction in the cell migrated area with respect to 
siCTR cells in Primary hFTSEC and all epithelial ovarian cancer cells 
(SKOV3, KURAMOCHI, OVSAHO and PEA1) (Fig 13). 
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Fig. 13 Effect of PAX8 silencing on the migration ability of Primary hFTSEC, SKOV3, 
KURAMOCHI, OVSAHO and PEA1 cell lines. The cell migrated area was measured 
after 48 hrs of transient transfection with PAX8 siRNA (grey bars) or scramble siRNA 
(black bars). The values are means ± SD of three independent experiments normalized 
with respect to the cells transfected with the scramble siRNA. p-value was calculated by 
t-test p ≤ 0.1. 
 
 
4.6 Analysis of the cell adhesion ability of the Fallopian tube secretory 
cells and ovarian cancer cell lines after PAX8 silencing 
 
The RNA-seq analysis showed that PAX8 is able to modify the 
expression of several adhesion molecules like Wnt7a, Cdh6, Cdh16, 
βActin and Integrin β3 genes. Whether this functionally affects the 
adhesive properties of ovarian tumor cells is not clearly understood. 
Therefore, to understand the consequences of the loss of PAX8 in cell-
matrix adhesive properties, the ability of the cells to adhere to different 
extracellular matrices (ECM) was addressed. The adhesive abilities of the 
Primary hFTSEC, SKOV3, KURAMOCHI, OVSAHO and PEA1 cell 
lines were evaluated through cell adhesion assays using Fibronectin and 
Collagen I as substrates to mimics the ECM. Upon PAX8 silencing the 
Primary hFTSEC, SKOV3, KURAMOCHI, OVSAHO and PEA1 cell 
lines adhered more slowly when cultured on Fibronectin and Collagene I-
coated coverslips with respect to siCTR-cells and showed significantly 
reduced adhesion after 2 hrs (Fig. 14 A, B, C, D, E). Overall, these results 
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suggest that PAX8 silencing could modify the expression of certain 
adhesion molecules in epithelial ovarian cancer cell lines like Integrins. 
Interestingly, Integrin expression is directly implicated in the progression 
of tumor and in formation of metastases.  
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Fig. 14 Effect of PAX8 silencing on the adhesion ability to Fibronectin or Collagen I of 
Primary hFTSEC (A), SKOV3 (B), KURAMOCHI (C), OVSAHO (D) and PEA1 (E). 
The values are means ± SD of three independent experiments normalized with respect to 
the cells transfected with the scramble siRNA. p-value was calculated by t-test p ≤ 0.1.  
 
 
4.7 PAX8 modulates tumor cell adhesion by regulating Integrin β3 
expression 
 
The altered interaction upon PAX8 silencing of Primary hFTSECs and 
ovarian cancer cells with ECM suggest a possible effect on the Integrin 
function. The RNA-seq analysis shows that Integrin β3 is amongst the 
genes significantly downregulated after PAX8 silencing in SKOV3 cells. 
Real-time qPCR was performed on Primary hFTSEC, SKOV3, 
KURAMOCHI, OVSAHO and PEA1 cell lines to understand if the 
expression of Integrin β3 (ITGB3) was modified after PAX8 silencing. All 
the cell lines were transfected with siCTR and siPAX8 as previously 
described. After 48 hrs of transfection, cells were harvested, the RNA 
extracted and cDNA synthetized. The results of the Real-time qPCR 
analysis confirmed the reduction in the expression levels of PAX8 in all 
siPAX8 cells when compared to siCTR cells. Then, the expression level 
of ITGB3 was examined and interestingly, ITGB3 expression level 
showed strong decrease in all cell lines after PAX8 silencing (Fig. 15).  
 
ITGB3 is reported to bind to only two other Integrins: Integrin αIIb and 
integrin αv. The expression of αIIbβ3 dimers is restricted to cells of the 
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megakaryocyte lineage and is required for platelet aggregation (Giancotti 
and Ruoslahti 1999). The αvβ3 integrin is expressed on proliferating 
endothelial cells and some cancer cells. There is evidence for the role of 
αvβ3 in multiple mechanisms of tumor growth and invasion, including 
interaction with ECM components, matrix metalloproteinase 2, platelet-
derived growth factor, insulin, VEGF receptors, and prevention of 
apoptosis (Kris A DeMali et al. 2003). Recently, its expression is 
observed in ovarian cancer cells and its potential as a therapeutic target 
for blocking tumor-induced angiogenesis is being considered (Kobayashi 
et al. 2017). To this end, a Real-time qPCR was performed to analyze the 
expression level of Integrin αv (ITGAV) after PAX8 silencing.  No 
change in the expression level of ITGAV was found after PAX8 silencing 
in all the cell lines (Fig. 15).  
 
To investigate the modulation of the Integrin αvβ3 heterodimer by PAX8, 
an immunofluorescence checking Integrin αvβ3 expression was performed 
on Primary hFTSECs and KURAMOCHI before and after PAX8 
silencing. After 48 hrs of transfection with siPAX8 and siCTR, the cells 
were fixed on coverslips as described before and were stained with Anti-
PAX8, Anti-Integrin αvβ3 antibody and HEOCHST for the nuclei. As 
showed in Figure 14, the lower intensity of the signal of PAX8 antibody 
in siPAX8-Primary hFTSECs and siPAX8-KURAMOCHI cells was a 
confirmation of PAX8 silencing (Fig. 16). Interestingly, the same result 
was observed for the signal of the Integrin αvβ3 antibody in both silenced 
cell types with respect to the control cells. In conclusion, we have 
established a correlation between PAX8 and Integrin αvβ3. This should be 
further explored to get better insights about the role of PAX8 in HGSC 
development and metastasis. 
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Fig. 15 Expression levels of PAX8 (black bars) ITGB3 (gray bars) and ITGAV (white 
bars) genes measured on total RNA prepared from Primary hFTSEC, SKOV3, 
KURAMOCHI, OVSAHO and PEA1 cells after 48 hrs of transiently transfection with 
PAX8 siRNA (siPAX8) or scramble siRNA (siCTR). The values are means ± SD of 
three independent experiments in duplicate, normalized by the expression of ABL and 
expressed as fold change with respect to the siCTR cells, whose value was set at 1.0. p-
value was calculated by t-test 0.001 ≤ p ≤ 0.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PR
IM
AR
Y h
FT
 si
PA
X8
SK
OV
3 s
iPA
X8
KU
RA
MO
CH
I s
iPA
X8
OV
SA
HO
 si
PA
X8
PE
A1
 si
PA
X8
0.0
0.5
1.0
1.5
2.0
Fo
ld
 c
ha
ng
e
PAX8
ITGB3
ITGAV
***
**
*** *** *** **
** **
**
**
Results 
	   46	  
 
 
 
 
Fig. 16 Primary hFTSEC and KURAMOCHI cells were transfected with scramble 
siRNA (siCTR) and PAX8 siRNA (siPAX8) and after 24 hrs were plated on coverslips 
and maintained in culture for 24 hrs. The confocal fluorescence analysis was 
performed for Integrin αvβ3 (red channel) and PAX8 (green channel). HEOCHST (blue 
channel) was used to locate the nuclei (scale bar 10 µm). The images are representative 
of three independent experiments. 
 
4.8 PAX8-ITGB3 molecular networks by Cytoscape 
 
To further investigate the PAX8-ITGB3 network that possibly governs 
migration and adhesion in the Ovarian carcinoma context, we reanalyzed 
our RNA-seq data using the Cytoscape platform. To begin understanding 
the possible interactors of PAX8, we used Cytoscape to perform network 
analysis before and after PAX8 silencing in SKOV3. As a validation of 
our experimental results, ITGB3 appeared as one of the most probable 
first interactors of PAX8 in SKOV3 (Figure 17). To have better insights 
into the PAX8-ITGB3 regulatory network, we performed a putative gene 
network analysis involving ITGB3 as a mediator of PAX8 in cell-cell 
KURAMOCHI siCTR 
KURAMOCHI siPAX8 
Integrin αvβ3 PAX8 HEOCHST MERGE 
Primary hFTSEC siCTR 
Primary hFTSEC siPAX8 
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interaction (contact inhibition) and cellular adhesion (tumor growth). 
Figure 18, shows the indirect targets of PAX8 regulated by its first 
interactor, ITGB3. The targets of ITGB3 show two kinds of interactions – 
radially pointed outwards and circularly interlinked – demonstrating 
different regulatory pathways. Most of these targets through ITGB3 are 
involved in tumor metastasis by various mechanisms like angiogenesis, 
cell migration, contact inhibition. It is important to note that the thickness 
of the arrow indicates the strength of the interaction and the color of 
arrows indicates the biological importance of the interactions. It is further 
interesting to note that upon PAX8 silencing in SKOV3 all its first 
interactors including ITGB3 and its associated targets are muted (Fig. 19). 
This is demonstrated by the decrease in cell adhesion and migration upon 
PAX8 silencing, which is reflected again on the network analysis of 
PAX8 –ITGB3 where the network collapses and other interaction are 
formed because there is no PAX8 or ITGB3 to regulate the network.  
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Fig. 17 Cytoscape analysis of PAX8-ITGB3 network in SKOV3 cells. 
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Fig.18 Cytoscape analysis of PAX8-ITGB3 network before PAX8 silencing in SKOV3 
cells. 
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Fig.19 Cytoscape analysis of PAX8-ITGB3 network after PAX8 silencing in SKOV3 
cells. 
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5. DISCUSSION AND CONCLUSION 
 
Epithelial ovarian cancer (EOC) is the one of the most common 
gynecological malignancies and the fifth leading cause of cancer-related 
death in women (Siegel et al. 2015). EOC is a highly metastatic cancer 
characterized by widespread peritoneal dissemination and ascites 
accumulation. It is typically diagnosed in advanced stages due to earlier 
symptoms (McKnight et al. 2010). Currently, there are no early stage 
biomarkers available and the standard treatment of EOC is surgery 
followed by repeated cycles of platinum- and taxane-based chemotherapy. 
However, the 5-year survival rate of patients with advanced-stage EOC is 
only 30%, caused by rapid development of drug resistance. Until now, the 
exact process of HGSC development is still obscure. Historically, the 
primary site of most epithelial ovarian cancers and in particular of HGSC 
was thought to be the ovarian epithelial surface. However, more recently 
it has been suggested that the cells that give rise to the majority of HGSC 
are from the fallopian tube fimbria (Karst et al. 2011; Quartuccio et al. 
2016). These findings opened up new opportunities for early detection, 
prevention and treatment of ovarian cancer. Throughout the oncogenic 
process, the secretory cells of the Fallopian tubes retain PAX8 expression 
that possibly continues to exert its transcriptional activity on its 
physiological targets and may also function on newly available targets 
after the tumorigenic hits. Nevertheless, the role that PAX genes play in 
cancer is still unclear. However, it has been demonstrated that PAX8 
could have important roles in the acquisition of the malignancy. In fact, 
the expression or overexpression of PAX proteins per se does not appear 
to be an initiating or a transforming molecular event in tumor 
pathogenesis, but could facilitate malignant development by controlling 
apoptotic resistance, tumor cell proliferation and migration, repression of 
terminal differentiation. The research group of Dr. Zannini in 2014 
reported that PAX8 is involved in the tumorigenic phenotype of ovarian 
cancer cells. Specifically, they showed that PAX8 plays a critical role in 
migration, invasion and tumorigenic ability of ovarian cancer cells. In 
addition, PAX8 silencing strongly suppresses anchorage-independent 
growth in vitro and significantly inhibits tumorigenesis in vivo in a nude 
mouse xenograft model (Di Palma et al. 2014). 
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To understand the role of PAX8 in the oncogenic process beginning in 
Fallopian tube secretory cells and proceeding into metastatic epithelial 
ovarian cancer, we analyzed the transcriptome of normal and transformed 
cells upon PAX8 silencing. The results of our RNA-seq analysis strongly 
suggest that PAX8 could be involved in cell adhesion, migration and 
angiogenic pathways in both cell lines. Supporting this, in the second part 
of my PhD project, we demonstrate that PAX8 is indeed involved in the 
migration and adhesion of both primary human Fallopian tube secretory 
epithelial cells (Primary hFTSECs) and ovarian cancer cell lines 
(SKOV3, KURAMOCHI, OVSAHO and PEA1). In particular, we show 
that PAX8 silencing in Primary hFTSECs and ovarian cancer cells 
significantly affects the migration ability with respect to control cells. 
Moreover, upon PAX8 silencing in Primary hFTSECs and ovarian cancer 
cells display significantly less adherence when cultured on Fibronectin- or 
Collagen I-coated coverslips. Interestingly, Real-time qPCR analysis 
showed a significant downregulation of Integrin β3 expression upon 
PAX8 silencing which correlates with the impairment of cell migration 
and adhesion in all cell lines used in this study. 
Integrins are transmembrane glycoproteins that facilitate cell-cell and 
cell-extracellular matrix (ECM) adhesion and migration. They are 
obligate heterodimers that have two subunits: α (alpha) and β (beta). In 
mammals, 18 α and 8 β subunits have been identified, which combine to 
give 24 different αβ heterodimers (Hynes 2002). Upon ECM ligand 
binding, integrins are capable of modulating a variety of intracellular 
signal transduction cascades that mediate cellular signals such as 
regulation of the cell cycle, organization of the intracellular cytoskeleton 
and movement (Giancotti and Ruoslahti 1999; Kris A. DeMali et al. 
2003). Integrin β3 has been already implicated in a wide variety of 
functions, including platelet aggregation and thrombosis, implantation, 
placentation, angiogenesis, bone remodeling, and tumor 
progression.  Integrin β3 null mice show defects in angiogenesis, bone 
remodeling and homeostasis, with placental defects that lead to fetal 
mortality (Hodivala-Dilke et al. 1999). Integrin β3 is able to pair with two 
subunits: αv and αIIb. Amongst integrins that have been identified as 
important mediators of ovarian cancer metastasis, the heterodimer 
Integrin αvβ3 holds a significant position. Integrin αvβ3 targeted either by 
antibodies or by small molecule inhibitors has been shown to inhibit 
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migration, adhesion, motility, angiogenesis, and proliferation in ovarian 
cancer cells in vitro (Carreiras et al. 2002; Markland et al. 2002; Leroy-
Dudal et al. 2005).  
To understand if PAX8 silencing could affect Integrin αvβ3 functional 
dimers in our cellular context, we performed an immunofluorescence 
using an antibody that specifically recognizes the heterodimer. It is 
interesting to note that αvβ3 heterodimer formation is entirely abrogated 
upon PAX8 silencing in both Primary hFTSEC and KURAMOCHI cells 
demonstrating the involvement of PAX8 in cell migration.  
 
In conclusion, this study demonstrates that: 
a) PAX8 silencing strongly affects the transcriptome of Fallopian tube 
secretory epithelial cells and ovarian cancer cells. Genes modulated by 
PAX8 in both cell types could be looked at as promising putative targets 
of this transcription factor whose function in this context is still unknown; 
b) Retention of PAX8 from the initial hit in Fallopian tube secretory cells 
throughout the development of epithelial ovarian cancer occurs possibly 
because PAX8 confers a survival advantage to the cancer cells and maybe 
even drug resistance. Our results offer an interesting support for this 
selective advantage by demonstrating the regulatory role of PAX8 on 
Integrin β3 and its functional dimer Integrin αvβ3. 
It is important to highlight that this is the first study reporting the 
correlation between PAX8 and Integrin β3 suggesting a possibly novel 
functional pathway in both normal and cancer context. We also 
demonstrate that PAX8 silencing affects the heterodimer Integrin αvβ3 
reported to be used in integrin-based strategy to enhance tumor specific 
recognition of nanocarries and shown to be effective for several integrin 
inhibitors that are capable of blocking cancer progression (Kobayashi et 
al. 2017). Hence, this study is of great relevance because PAX8 targeted 
therapies for HGSC could be more promising and more specific than 
generic Integrin αvβ3 targeted therapies that acquire drug resistance over 
time. 
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